Sartorius Stedim Biotech to acquire Albumedix from private investors for £415m.

Sartorius-backed Sartorius Stedim Biotech, a provider of total solutions for the biopharmaceutical Industry, agreed to acquire Albumedix, an albumin focused biotechnology company, from private investors for £415m. “Albumedix will be an important addition to Sartorius Stedim Biotech’s advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones,” René Fáber, Sartorius Stedim Biotech member of the Board of Directors and Deputy CEO.